Anticoagulant, Fragmin, receives FDA approval for pediatric use
by Press Release from Outbreak News Today on (#4FC3C)
The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older. VTE can include deep vein thrombosis (blood clot in the deep veins of the leg) and pulmonary embolism (blood clot in the ["]
The post Anticoagulant, Fragmin, receives FDA approval for pediatric use appeared first on Outbreak News Today.